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Introduction
In Regenerative Medicine one or more regenerative factors
can be applied inside a cartilagine or bone defect to obtain
a more rapid and complete healing. Bone Marrow Cells
(BMC) added to Platelet-Rich Plasma (PRP) contain stro-
mal cells which can differentiate in osteoclasts and osteo-
blasts and can be able to form osteogenic tissue and to
repair bone defects secondary to degenerative processes.
Objectives
We report 2 cases in which we implanted BMC plus PRP
in the osteonecrotic region with a clinical and imaging
follow-up.
Methods
The first case is a 17-year old boy, followed at our
Department, affected by JIA since he was 2 years old. He
presented a systemic form, evolved into a polyarticular
form, treated with steroids and immunosuppressor drugs.
The patient had a good response to treatment with
Enbrel, which he is still taking. In January 2009, he pre-
sented right hip pain and functional limitation. In July
2009 he underwent MRI of the hip joints which showed
osteonecrosis in chondral/subchondral regions at the
superior-external convexity of the right femoral head.
We recommended deambulation with crutches and no
weight bearing. Because of the persistence of joint symp-
toms, in July 2010 we implanted BMC plus PRP in the
osteonecrotic region with improvement of pain and
mobilization. In October 2010, he presented left hip pain.
MRI showed focal osteonecrosis in subchodral region of
left femoral head convexity. For this reason, we made a
second BMC plus PRP implantation in the left hip. The
MRI, made on January 2012, showed any changes con-
cerning the morphology of femoral heads and subchon-
dral erosions. The last MRI, made on December 2012
showed no changing of lesions and a mild improvement
of right hip. Our patient autonomous walks, without
joint pain and with improved hip movements, since Janu-
ary 2011; he keeps on Enbrel and nsaids. The second
case is a 20-year and 4 month old girl with extended oli-
goarticular JIA diagnosed when she was 2 years old. On
July 2012 after an injury, a flare occurred in the left knee.
MRI, made on October 2012 showed intra-articular
effusion with diffuse synovial thickening, small bone
subchondral erosions of medial femoral condyle. She
underwent a surgical procedure where we implantated
BMC plus PRP on January 2013 which resulted in
improvements of mobility and reduction of pain.
Results
All two patients had an improvement of their mobility and
pain reduction with no progression of articular damages
on MRI imaging.
Conclusion
To the best of our knowledge, there are no literature data
on the use of BMC plus PRP in pediatric patients affected
by JIA. Considering the obvious limitations of our case
reports, we observed a good short-term outcome. There-
fore, follow-up is essential to check if BMC plus PRP
implantation represents only a palliative care to delay
1Pediatrics, Istituto G. Gaslini, Genova, Italy
Full list of author information is available at the end of the article
Salvati et al. Pediatric Rheumatology 2013, 11(Suppl 2):P104
http://www.ped-rheum.com/content/11/S2/P104
© 2013 Salvati et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.





1Pediatrics, Istituto G. Gaslini, Genova, Italy. 2Istituto G. Gaslini, Genova, Italy.
3Service of Immuno-Hematology and Transfusion Medicine, Instituto G.
Gaslini, Genova, Italy. 4Pediatric Surgery, Istituto G. Gaslini, Genova, Italy.
Published: 5 December 2013
References
1. Gothard D, et al: Lab Chip 2011, 11(7):1206-20.
2. Nauth A, et al: J Orthop Trauma 2010, 24(9):543-6.
3. Calori GM, et al: Injury 2009, 40(Suppl 3):S67-76.
doi:10.1186/1546-0096-11-S2-P104
Cite this article as: Salvati et al.: PReS-FINAL-2092: Bone marrow cells
(BMC) added to platelet-rich plasma (PRP) for treatment of bone
degenerative processes in JIA patients: follow-up of 2 cases. Pediatric
Rheumatology 2013 11(Suppl 2):P104.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Salvati et al. Pediatric Rheumatology 2013, 11(Suppl 2):P104
http://www.ped-rheum.com/content/11/S2/P104
Page 2 of 2
